Evommune EVMN Income Statement
| FY'25 | ||
|---|---|---|
| $6.61M— | ||
| $3.13M— | ||
| $3.48M— | ||
| 52.7%— | ||
| $632.41K— | ||
| $4.25M— | ||
| $4.88M— | ||
| -$1.4M— | ||
| -21.2%— | ||
| $402.4K— | ||
| —— | ||
| —— | ||
| -$1.4M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Evommune 's revenue?
- Evommune (EVMN) generated $6.7M in revenue over the trailing twelve months.
- Is Evommune profitable?
- Evommune is not currently profitable: it reported a net loss of $6.0M over the trailing twelve months, a -90.1% net margin.
- What are Evommune 's profit margins?
- Gross margin is 53.7% and operating margin is -30.7%, with a -90.1% net margin.
- What is Evommune 's earnings per share?
- Evommune 's diluted EPS over the trailing twelve months is $-0.32.
- Where does Evommune 's income statement data come from?
- Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
